We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Highlights Primary and secondary endpoints met in the Phase 2a study of DMX-200 in FSGS patients DMX-200 was found to be generally safe and well-tolerated in FSGS patients 86% of patients...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.005 | -1.47058823529 | 0.34 | 0.3575 | 0.32 | 902107 | 0.33906778 | DE |
4 | -0.06 | -15.1898734177 | 0.395 | 0.405 | 0.3 | 1276903 | 0.36024078 | DE |
12 | -0.05 | -12.987012987 | 0.385 | 0.51 | 0.3 | 2087448 | 0.40077687 | DE |
26 | -0.17 | -33.6633663366 | 0.505 | 0.665 | 0.3 | 3044548 | 0.46535375 | DE |
52 | 0.205 | 157.692307692 | 0.13 | 0.665 | 0.13 | 3515397 | 0.37201929 | DE |
156 | 0.095 | 39.5833333333 | 0.24 | 0.665 | 0.052 | 1737733 | 0.30281871 | DE |
260 | 0.205 | 157.692307692 | 0.13 | 0.78 | 0.052 | 1441712 | 0.30445802 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions